Q-omics provides the consensus-scored MROH5 profile across patient tissues and cancer cell-line models. MROH5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MROH5 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, MROH5 RNA expression shows 14,286 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KICH, and THYM as cancer lineages where MROH5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MROH5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MROH5 survival associations across molecular data types. MROH5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MROH5 RNA expression–survival associations across cancer types. High MROH5 expression shows unfavorable associations in UVM, KIRC, COAD, DLBC and BRCA, but favorable associations in PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MROH5 RNA expression.
This table summarizes MROH5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MROH5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MROH5 shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in THCA, COAD and KIRC. The KICH box plot shows higher MROH5 RNA expression in normal versus tumor tissue (log2 FC = −0.062, t-test p = .001).
This table shows molecular features associated with MROH5 in patient tissues and cancer cell lines. In patient samples, MROH5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MROH5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
